Shouse Covers the Future of Lymphoma Therapy With Bispecific Antibodies

Geoffrey Shouse, DO, PhD, an assistant professor at City of Hope Comprehensive Cancer Center in Duarte, California, and a member of the lymphoma division, discusses the growing interest in bispecific antibodies within the field of oncology. He specifically highlights their growing role for the treatment of patients with diffuse large B-cell lymphoma.

He highlights the collaborative efforts of several consortia working to gather and analyze data on these therapies. Shouse notes that City of Hope, his institution, is part of a network of over 10 centers contributing to this research, which aims to compile larger datasets on patient outcomes.

The goals of this work include evaluating the efficacy and safety of FDA-approved bispecific antibodies, as well as identifying predictors of treatment outcomes and toxicity. In addition, Shouse emphasizes the importance of examining not only clinical outcomes but also broader issues such as financial toxicity, social challenges, and access barriers that patients may face.

Transcription:

0:10 | I know that there are a couple kinds of consortia working together that are trying to pull data about bispecific antibodies. We are contributing to a group of more than 10 centers and we are getting much higher numbers in terms of patients with bispecific antibodies. We are going to be looking individually at outcomes with each of the agents that are FDA-approved, and then kind of taking deeper dives and looking—trying to drill into predictors of outcomes, predictors of toxicity, even financial toxicity and social issues, as well as access issues for bispecifics.

0:51 | [Bispecifics] really do seem to be a very beneficial therapy for patients with large cell lymphoma. And so, identifying how we can safely get this treatment to patients and get it to patients at all, I think, are important questions that will hopefully be evaluated and answered in the coming months.